Emotion and Memory in Chronic Neuropathic Pain

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35-60
SponsorUniversity Health Network, Toronto

About this trial

Chronic pain affects one in four Canadians, leading to severe personal and societal costs. Over 70% of chronic pain patients report memory difficulties and fear having unexpected pain. Abnormalities in brain structures associated with emotion and memory, including the hippocampus and amygdala, can be affected by chronic pain. Understanding the relationship between chronic pain, structural brain changes, and cognitive functioning will lead to improved diagnosis, treatment, and outcomes in chronic pain disorders. In this project, the investigators will use advanced brain imaging techniques that assess the structure and function of the brain along with cognitive assessments to examine the overlap between chronic pain and emotion-memory processes. The study team will conduct the study using an excellent model of chronic pain-trigeminal neuralgia, a severe form of facial pain that responds well to surgical treatment. Brain images and cognitive data will be collected from participants before and after surgical treatment for pain. This information will be analyzed and compared with age- and sex-matched healthy individuals. This study will be the first to thoroughly investigate relationships between brain structure and function, cognition (memory, emotion), and promises to impact our understanding of chronic neuropathic pain conditions.

Eligibility criteria

Qualifiers

Age between 35 and 60 years old

Absence of other active major neurological or psychiatric disorders

Absence of MRI contraindications

Able to communicate sufficiently to complete tasks and questionnaires

Disqualifiers

Presence of other chronic pain/headache conditions

Untreated hypertension or diabetes mellitus

History of chronic drug or substance use disorder, chronic use of opioids or steroids, head trauma affecting cognitive performance,

History/presence of active psychiatric illness and/or current use of psychoactive medication

Trial design

Treatments tested in this trial

  • Neuropsychological assessments
  • MR Imaging

Treatment groups

400 Participants
are divided into 2 treatment groups